Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Sponsor: Memorial Sloan Kettering Cancer Center

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT00107289

Patient View

This study evaluates the safety and efficacy of ^131I-MIBG in patients with resistant neuroblastoma, pheochromocytoma, or paraganglioma. Participants receive an initial dose of ^131I-MIBG, with potential for a second dose based on response and toxicity. Eligibility includes patients with recurrent, progressive, or refractory conditions. Follow-up occurs at 4-6 weeks and every 3 months for a year.

Patient Parameters

Program Overview

The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.

Eligibility Criteria

Exclusion Criteria

  • Severe major organ toxicity. Specifically, renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 2 or less. A grade 3 hearing deficit is acceptable.
  • Active serious infections not controlled by antibiotics.
  • Pregnant women are excluded for fear of danger to the fetus. Therefore negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is used during the study period.
  • Inability or unwillingness to comply with radiation safety procedures or protocol requirements.

Get This Program In Your Inbox

You can sign up and apply your patients for this program.